31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The cohort study revealed that persistent HI significantly increased the risk of heart disease (P < 0.001, HR 1.63, 95% CI 1.31-2.03), stroke (P 0.004, HR 1.59, 95% CI 1.16-2.18), chronic lung disease (P 0.002, HR 1.53, 95% CI 1.17-1.99), and emotional, nervous, or psychiatric problems (P 0.016, HR 2.03, 95% CI 1.14-3.60). 5 key findings →
Design: cohort study Participants: 504,307 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Subjects experiencing multisensory impairments concurrent with visual impairment demonstrated a negative association with cognitive function. 5 key findings →
Design: cohort study Participants: 500,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Increased absolute sugar intake (g/day) was significantly associated with a higher risk of all-cause dementia (HR = 1.003, [95%CI: 1.002-1.004], p < 0.001) and Alzheimer's disease (1.002, [1.001-1.004], 0.005). 5 key findings →
Design: cohort study Participants: 210,832 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of 65 participants with biomarker-confirmed AD, 21 (32.3%) were αS-SAA positive. 4 key findings →
Design: longitudinal study Participants: 108 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These results suggest that flortaucipir PET scans, when interpreted with an US Food and Drug Administration-approved, clinically applicable visual interpretation method, may provide valuable information regarding the risk of clinical deterioration over 18 months among patients with AD and MCI. 3 key findings →
Design: longitudinal study Participants: 174 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Antipsychotic use compared with non-use in adults with dementia was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, and acute kidney injury, but not ventricular arrhythmia. 5 key findings →
Design: cohort Participants: 173,910 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In BioFINDER-2, the mean (SD) age was 65.7 (14.4) with 261 females (52.7%). 3 key findings →
Design: cohort Participants: 983 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P Conclusions and relevance The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs. 3 key findings →
Design: cohort study Participants: 1,583 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 16 008 registered participants, 11 409 (71.3%) completed study procedures and were included in the analysis (median age, 75 years [interquartile range, 71-80]; 50.9% women; 60.5% with MCI). 5 key findings →
Design: longitudinal study Participants: 16 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We also determined the extent to which sex, educational attainment, and apolipoprotein E ε4 allele (APOE*4) carrier status were associated with decline. 2 key findings →
Design: cohort study Participants: 42,170 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our random 20% sample included 848,303 fee-for-service Medicare decedents (mean age, 82.3 years; 57.9% female, 88.1% white). 2 key findings →
Design: cohort study Participants: 270,202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease (AD). 4 key findings →
Design: longitudinal study Participants: 115 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease (AD), their broad implementation in clinical and trial settings are restricted by high cost and limited accessibility. 3 key findings →
Design: longitudinal study Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
An estimated 8.8 million Indians older than 60 years have dementia. 2 key findings →
Design: longitudinal study Participants: 2,528 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The presence of multiple cardiovascular risk factors at midlife substantially increases risk of late-life dementia in a dose dependent manner. 5 key findings →
Design: cohort study Participants: 8,845 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. 5 key findings →
Design: longitudinal study Participants: 6,514 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Mediterranean diet (MD) has shown to reduce the occurrence of several chronic diseases. 4 key findings →
Design: cohort study Participants: 16,160 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 6321 participants (mean [SE] age, 56.1 [0.18] years at visit 1; n = 4077 women [57.8%]) were included. 3 key findings →
Design: cohort study Participants: 4,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cohort studies suggest that the Mediterranean diet is associated with better global cognition in older adults, slower cognitive decline and lower risk of dementia. 5 key findings →
Design: cohort study Participants: 249,511 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. 4 key findings →
Design: cohort study Participants: 258 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In patients without baseline cognitive dysfunction, short-term data are most compatible with no adverse effect of statins on cognition, and long-term data may support a beneficial role for statins in the prevention of dementia. 3 key findings →
Design: cohort study Participants: 23,443 Evidence: high
Full summary, score breakdown and related studies → Original source
In this cohort study of US Medicare beneficiaries, dual sensory impairment was prevalent in older adults and associated with increased risk of dementia. 5 key findings →
Design: cohort study Participants: 7,562 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Benefits and risks of statins relative to neurological outcomes should be considered when prescribed for at-risk NDD populations. 3 key findings →
Design: cohort study Participants: 288,515 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with CKD could have an elevated dementia risk. 4 key findings →
Design: cohort study Participants: 37,049 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau 217 and the NfL/p-tau 217 ratio are promising non-invasive biomarkers for differentiating AD from FTLD, suggesting their use as a potential alternative to traditional diagnostic methods. 2 key findings →
Design: cohort study Participants: 374 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events